One factor that seems to be involved is C5a, a protein involved in chemotaxis. Theoretically, blocking C5a receptor (C5aR) activity could form a therapeutic strategy for RA. The recently developed ...

Their lead product candidate, vilobelimab, is an anti-C5a monoclonal antibody, and INF904 is a small molecule inhibitor of the C5a receptor. The company was established in 2007 and maintains ...

InflaRx's Gohibic, a novel anti-C5a monoclonal antibody, has been authorized for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are also ...

Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of ...